|
NIBM Update 09-21-2002 (Number 12) |
|
- Cover -
More setbacks than successes
- Page 2 -
Macro Market Notes & Analysis
- Page 3 -
NIBM Model Portfolio Updates
-
(ALT, GNTA, IDBE, ALLP)
- Page 4 -
News Briefs
- Fabrazyme and Replagel postponed, Iressa on track
- Pfizer punts Onyx's GT platform
- Liposcience IPO delayed
-
Novartis woos Massachusetts biotechs
-
Spiriva gains FDA committee nod for
COPD
-
CDC/CBER announce flu vaccine
availability
|
 |
|
| NIBM Updates are
available only to subscribers. In each update we analyze current market trends inside and
outside the biotech market sector. We also provide updates on the companies that appear in
our monthly NIBM Newsletter. Click on the box above to become a
subscriber today! |
Subscriber direct access |
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
